Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of CARA opened at $5.36 on Tuesday. The firm has a 50-day simple moving average of $3.91 and a two-hundred day simple moving average of $3.78. The stock has a market cap of $294.03 million, a PE ratio of -3.06 and a beta of 0.64. Cara Therapeutics has a 1-year low of $2.71 and a 1-year high of $13.80.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Disciplined Growth Investors Inc. MN lifted its position in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares in the last quarter. FMR LLC grew its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics during the third quarter worth $29,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.